U.S. markets open in 9 hours 20 minutes
  • S&P Futures

    4,702.25
    +17.25 (+0.37%)
     
  • Dow Futures

    35,802.00
    +89.00 (+0.25%)
     
  • Nasdaq Futures

    16,396.25
    +78.25 (+0.48%)
     
  • Russell 2000 Futures

    2,265.20
    +11.30 (+0.50%)
     
  • Crude Oil

    71.88
    -0.17 (-0.24%)
     
  • Gold

    1,790.10
    +5.40 (+0.30%)
     
  • Silver

    22.51
    -0.01 (-0.06%)
     
  • EUR/USD

    1.1297
    +0.0024 (+0.21%)
     
  • 10-Yr Bond

    1.4800
    +0.0460 (+3.21%)
     
  • Vix

    21.89
    -5.29 (-19.46%)
     
  • GBP/USD

    1.3250
    +0.0009 (+0.06%)
     
  • USD/JPY

    113.4900
    -0.0500 (-0.04%)
     
  • BTC-USD

    50,215.77
    -1,020.12 (-1.99%)
     
  • CMC Crypto 200

    1,299.27
    -22.01 (-1.67%)
     
  • FTSE 100

    7,339.90
    +107.62 (+1.49%)
     
  • Nikkei 225

    28,880.25
    +424.65 (+1.49%)
     

Eli Lilly's Tirzepatide Non-Inferior To Titrated Insulin Glargine In Type 2 Diabetes Patients

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Eli Lilly and Co (NYSE: LLY) has reported topline data from Phase 3 SURPASS-4 clinical trial evaluating tirzepatide in adults with type 2 diabetes and increased cardiovascular risk.

  • Measuring the GLP-1 receptor agonist tirzepatide against titrated insulin glargine, Lilly reported that its program hit all primary and key secondary endpoints across three dosage levels.

  • The primary endpoint was measured at 52 weeks, and many participants continued treatment beyond 52 weeks, some up to two years.

  • It’s the fifth Phase 3 study Lilly has completed for the candidate, and now it plans to submit details to regulatory authorities later in 2021.

  • Participants began the study with an average baseline A1C of 8.52%, and each of the treatment arms lowered the levels at a significant rate compared to titrated insulin glargine, Lilly said.

  • At one year, the changes for each escalating dose were -2.24%, -2.43% and -2.58%, against -1.44% for the control.

  • Tirzepatide reduced weight from the average baseline by 8.1%, 10.7%, and 13% for the three arms, respectively.

  • Meanwhile, participants in the titrated insulin glargine arm saw a mean weight increase of 2.2% relative to the baseline.

  • Lilly noted that the overall safety results in the study were consistent with the profile of the GLP-1 class, with gastrointestinal side effects proving to be the most common such as nausea, diarrhea, and vomiting.

  • Price Action: LLY shares closed at $196.5 on Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.